



### Plenary

1. Somatic mutations in pituitary tumors: M. Theodoropoulou (Germany)
2. Pituitary transcription factors, where are we?: S. Camper (USA)
3. Growth hormone receptor antagonists, from discovery to recent use: J. Kopchikh (USA)
4. Hypogonadotropic hypogonadism: N. Pitteloud (Switzerland)

### Symposia

#### 1. Changes in diagnostic paradigms

- State of the art: Classifying pituitary tumors: C. Villa (France)
- Old and new biomarkers of cortisol excess: A. Tabarin (France)
- Vasopressin deficiency diagnosis: M. Christ-Crain (Switzerland)
  - Is OGTT still useful in acromegaly?: G. Occhi (Italy)

#### 2. Improving the diagnostic strategy of Cushing's disease

- State of the art: Is imaging necessary to operate CD? M. Buchfelder (Germany)
  - 7T MRI: B. Testud (France)
  - PET-MRI in pituitary tumors: M. Gurnell (UK)
  - How to live without CRH: M. Puig Domingo (Spain)

#### 3. Multiomics in NET management: from bench to bedside

- State of the art: Multiomics classification of pituitary tumors: G. Assie (France)
- Circulating non coding RNA biomarkers of endocrine tumors: H. Butz (Hungary)
  - Proteomics: T. Skoglund (Sweden)
- Tadopathy as a cause of gigantism: A. Daly (Belgium)

#### 4. New kids on the block in pituitary function and interactions

- State of the art: Pituitary cells function as a network: P. Mollard (France)
  - Circadian rhythm and cortisol: S. Lightman (UK)
  - Microenvironment in pituitary tumors: R. Luque (Spain)
    - Pituitary stem cells: C Andoniadou (UK)

#### 5. Advances in the management of pituitary tumors

- Resetting the natural history of macroNFPA: N. Karavitaki (+ chair) (UK)
  - Can acromegaly be controlled in all cases?: S Chiloiro (Italy)
- How to avoid surgery in craniopharyngioma?: E. Jouanneau (France)
- Somatostatin receptors, from old to new concepts: D. Ferone (Italy)

#### 6. Controlling the secretion should not be the only aim of management

- State of the art: Unmet needs in patients in remission of pituitary tumors: E. Valassi (Spain)
- Altered quality of life in pituitary tumors, it begins at diagnosis: T. Marmorat (France)
- Neurocognitive consequences of pituitary tumors: A. Pereira (The Netherlands)
  - Living with a pituitary tumor: J. De Graaf (The Netherlands)

### Controversies

1. Dopamine agonists should not be the first line treatment of prolactinomas  
N. Biermasz (The Netherlands) vs. P. Nomikos (Greece)
2. Surgery or conservative management for pituitary apoplexy  
P. Chanson (France) vs. W. Van Furth (The Netherlands)